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Introduction: The aim of this practice guideline was to develop evi-
dence-based recommendations for screening high-risk populations 
for lung cancer.
Methods: The guideline was developed using the methods of Cancer 
Care Ontario’s Program in Evidence-Based Care. The core method-
ology of the Program in Evidence-Based Care’s guideline develop-
ment process is systematic review. A systematic review had recently 
been completed by a collaboration of the American Cancer Society, 
the American College of Chest Physicians, the American Society 
of Clinical Oncology, and the National Comprehensive Cancer 
Network. The evidence from that systematic review formed the basis 
of the recommendations, which were reviewed, and amended where 
necessary, by clinical experts in the fields of medical and radiation 
oncology, radiology, lung disease, and population health.
Results: The systematic review included eight randomized con-
trolled trials and 13 single-arm studies evaluating screening with 
low-dose computed tomography (LDCT) in patients at risk for lung 
cancer. One large randomized trial reported a statistically significant 
reduction in lung cancer mortality with LDCT at 6 years compared 
with chest radiography. The practice guideline recommendations 
generally align with the parameters of the National Lung Screening 
Study. Deviations were described and justified by the guideline work-
ing group. The recommendations support screening persons at high-
risk for lung cancer with advice for determining a positive result on 
LDCT, appropriate follow-up, and optimal screening interval.
Conclusion: The benefits of screening high-risk populations for lung 
cancer with LDCT outweigh the harms if screening is implemented 
in a strictly controlled manner.
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LUNG CANCER AND SCREENING
Lung cancer is the most common cause of cancer death 
in Ontario. Contributing to the high mortality rate is a lack of 
an effective evidence-based screening method. Using the two 
tests commonly used to screen for lung cancer, chest radio-
graph (CXR) and sputum cytology, has not demonstrated a 
reduction in mortality. Screening for lung cancer using low-
dose computed tomography (LDCT) has been the subject of 
research studies since the 1990s.1–3 In the intervening years, 
much has been learned about the detection of lung nodules 
using LDCT, the characterization of early lung cancers, and, 
more recently, the effect of LDCT on disease-specific mor-
tality. The National Lung Screening Trial (NLST) compared 
LDCT with CXR in high-risk populations and found a 20% 
reduction in lung cancer mortality at 6 years with LDCT after 
an initial scan and two annual rounds of screening.4 The NLST 
is the first randomized controlled trial (RCT) to show a mor-
tality benefit with lung cancer screening.
Some knowledge gaps still exist regarding the use of 
LDCT for lung cancer screening, including the balance of 
benefit and harm, the optimal group of at-risk individuals 
to screen, the frequency and duration of screening, and the 
cost-effectiveness across various health environments. Thus, 
LDCT screening is not yet part of the standard of care and 
no formal process currently exists in Ontario for lung cancer 
screening. However, physicians and patients are aware of the 
technique, and it has begun to be used without official guide-
lines. Injudicious use of LDCT can potentially cause more 
harm than benefit, including exposure of healthy persons to 
ionizing radiation and subsequent invasive procedures for ulti-
mately benign lesions. When used correctly, however, LDCT 
screening has the potential to save lives.
Guidelines on the appropriate use of LDCT for lung can-
cer screening are urgently needed for physicians and patients 
to avoid the ad hoc adoption of LDCT screening for lung 
cancer by hospitals and diagnostic centers and to minimize 
the risks associated with LDCT scanning (e.g., false positives 
leading to unnecessary invasive follow-up, overdiagnosis, and 
increased radiation exposure). This guideline focuses on clini-
cal effectiveness and safety considerations. Specifically, the 
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definition of a population at risk, the definition and follow-
up of a positive scan result, and the duration and interval of 
screening. Beyond the scope of this guideline are several key 
issues, including acceptability of LDCT to individuals, fea-
sibility of implementing LDCT, cost-effectiveness of LDCT 
screening, and an analysis of resource availability. These and 
other issues will need to be addressed before a lung cancer 
screening program can be implemented.
MATERIALS AND METHODS
The Program in Evidence-Based Care (PEBC) is an ini-
tiative of the Ontario provincial cancer system, Cancer Care 
Ontario.5 Its mandate is to improve the lives of Ontarians 
affected by cancer, through the development, dissemination, 
implementation, and evaluation of evidence-based products. 
The PEBC supports a network of disease-specific panels as well 
as other groups or panels called together for a specific project, 
all mandated to develop the PEBC products. The PEBC pro-
duces evidence-based and evidence-informed guidelines using 
the methods of the Practice Guidelines Development Cycle.5,6 
The report consists of an evidentiary base (typically a system-
atic review), an interpretation of and consensus agreement on 
that evidence by our groups or panels, the resulting recommen-
dations, and an external review by Ontario clinicians and other 
stakeholders in the province for whom the topic is relevant.
The supporting evidence for this guideline is primar-
ily contained in a systematic review from a collaboration of 
the American Cancer Society, the American College of Chest 
Physicians, the American Society of Clinical Oncology, and 
the National Comprehensive Cancer Network.7 The col-
laborative systematic review was reviewed by the guideline 
development group and deemed to be both of high quality 
and comprehensive and would amply serve as the evidentiary 
base for this practice guideline. The literature search per-
formed for the collaborative review retrieved relevant studies 
from MEDLINE, EMBASE, and the Cochrane Library up to 
April 2012. Eligible studies were RCTs that compared LDCT 
screening with another form of screening or no screening, or 
were noncomparative studies in which all participants were 
screened with LDCT. An update search using the strategy of 
the collaborative review was run in May 2012 to retrieve any 
relevant studies published since the original search was done.
Before undergoing external review, the report was 
reviewed by the PEBC Report Approval Panel, a panel that 
includes oncologists and whose members have clinical and 
methodological expertise, and an Expert Panel comprising 
lung cancer specialists and clinicians with expertise in screen-
ing and population health. The PEBC external review process 
is two-pronged and includes a targeted peer review that is 
intended to obtain direct feedback on the draft report from a 
small number of specified content experts and a professional 
consultation that is intended to facilitate dissemination of the 
final guidance report to Ontario practitioners.
RESULTS
Literature Search Results
The literature search identified 591 citations. Eight 
RCTs and 13 cohort studies met the eligibility criteria for the 
systematic review. The updated search identified an additional 
systematic review of six RCTs that were included in the col-
laborative review, and an RCT.
RECOMMENDATIONS, KEY EVIDENCE, AND 
JUSTIFICATION
Screening High-Risk Populations 
for Lung Cancer
The Working Group is in favor of screening high-risk 
individuals for lung cancer with LDCT. The primary evidence 
base for this proposal is the NLST, a large (>50,000 partici-
pants) RCT that compared LDCT screening with CXR and 
showed a 20% decrease in death from lung cancer in high-risk 
persons.4
The primary benefit associated with LDCT screening 
is a statistically significant reduction in mortality, both lung 
cancer specific and all-cause. LDCT can identify smaller 
nodules than can CXR and thus can detect lung cancer at an 
earlier stage when a cure is more possible. Under current cir-
cumstances, most lung cancer patients are diagnosed at an 
advanced stage, and lung cancer accounts for more than a 
quarter of all cancer deaths.8
LDCT screening is not without risk. Computed 
tomography (CT) scanning, with its acquisition of mul-
tiple images, exposes an individual to a greater radiation 
dose than does CXR and may place patients at increased 
risk of lung and breast cancer. On the basis of models from 
official bodies and commissioned studies of estimates of 
harm from radiation, Bach et al.7 estimate using the NLST 
data that one cancer death may be caused by radiation from 
imaging per 2500 persons screened. The serial CT scans 
required as part of a screening program necessitate judi-
cious and efficient use of the technology, with strict rules 
pertaining to quality control and training. The information 
obtained from a CT scan of the chest provides more precise 
visualization of lung nodules, leading to a higher rate of 
detection of lung nodules. Although the majority of these 
nodules (>90%) will be benign, the detection of these nod-
ules may lead to further imaging and follow-up that can 
involve invasive diagnostic procedures and possibly harm-
ful and unnecessary treatment. Completely addressing the 
clinical and cost implications of this high false-positive 
rate (e.g., in the NLST, 27% of scans were positive, and 
96% of those were false positive4) is critical and remains 
a challenge. In the interim, the Working Group endorses a 
strict application of screening to only a targeted high-risk 
population.
In general, the recommendations discussed subse-
quently reflect the parameters of the NLST.4 Where there 
are deviations from those parameters, we provide justifica-
tion. Although there are still ongoing trials comparing LDCT 
with usual care, none are as large (and therefore as statisti-
cally powerful) as the NLST, and it is unlikely that another 
trial the size of the NLST will be undertaken. Some aspects of 
the ongoing trials may affect the recommendations once their 
results are known, and we have qualified our recommenda-
tions to acknowledge these uncertainties.
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RECOMMENDATIONS AND SPECIFIC EVIDENCE
Main Recommendation
•  Recommendation 1: Screening for lung cancer with 
LDCT is recommended in high-risk populations defined 
as persons who are 55 to 74 years of age with a minimum 
smoking history of 30 pack-years or more (pack-years = 
number of cigarette packs smoked per day × the num-
ber of years smoked) who currently smoke or have quit 
in the past 15 years and are disease-free at the time of 
screening.
Key Evidence
•  Among the studies in the collaborative review, the age 
for initiation of screening ranged from 47 to 60 years 
in the RCTs and from 40 to 60 years in the single-
arm studies.7The upper age for screening ranged from 
69 to 80 years in the RCTs and from 73 to 85 years in 
the single-arm studies.7 The NLST initiated screening 
in persons aged 55 years or more and stopped at age 
75 years.4The minimum smoking history in the RCTs 
ranged from 15 or more to 30 or more pack-years and 
in the single-arm studies from 10 or more to 20 or more 
pack-years.7 The NLST enrolled persons with a smok-
ing history of 30 pack-years or more and former smokers 
who had quit in the past 15 years.4Seven RCTs reported 
previous cancer history in the eligibility criteria, stipulat-
ing a minimum number of years of being disease-free 
since a previous cancer diagnosis. These ranged from 5 
years to an indefinite period, with variations for differ-
ent types of cancers. Among 11 single-arm studies, this 
criterion was described as a minimum of 5 years since a 
previous cancer diagnosis, any previous lung cancer, any 
known pulmonary metastases, and any previous cancer 
diagnosis.7 In the NLST, exclusion criteria were: a pre-
vious diagnosis of lung cancer, a previous diagnosis of 
other cancer in the past 5 years, chest CT scan within 18 
months before enrollment, hemoptysis, or unexplained 
weight loss of more than 6.8 kg in the preceding year.4
Justification
•  There is no evidence to support a specific age to initi-
ate screening, a specific age to cease screening, or a 
specific screening frequency interval. The highest qual-
ity and most compelling evidence is from the NLST. 
As such, the parameters used in this trial were endorsed 
by the Working Group as clinically reasonable. Patient 
acceptability, cost effectiveness, feasibility, and system 
capacity may influence whether these parameters are 
reasonable and implementable.Smoking history is a sub-
jective risk factor and we acknowledge that it cannot be 
precisely measured. If smoking is begun in early adult-
hood (i.e., early 20s) as it commonly is, by age 50 to 55, 
most people will have exceeded 20 pack-years. Although 
the NLST enrolled participants with a minimum smok-
ing history of 30 pack-years, several other studies used a 
threshold of 20 pack-years or less. These studies had lung 
cancer detection rates similar to those of the NLST. It is 
anticipated that an increased detection rate would lead to 
a mortality reduction. The Working Group agreed on a 
30 pack-year smoking history threshold to recommend 
lung cancer screening, in accordance with the study entry 
criterion in the NLST. The panel will update this recom-
mendation when the results of the Nederlands-Leuven 
Longkanker Screenings Network (NELSON) trial 
(which had a 15 pack-year requirement) are published.9It 
is reasonable to define the screening population by age 
and smoking history, but there is currently insufficient 
evidence to include participants based on other risk fac-
tors such as family history, passive smoking, occupa-
tional exposure, radon exposure, previous cancer, and 
other diseases.
Qualifying Statements
Screening may be a reasonable option in persons with a 
smoking history of less than 30 pack-years. However, as this 
risk group was not included in the NLST, an explicit recom-
mendation in favor of screening such persons cannot be made 
at this time. A current trial (NELSON)9 includes patients with 
a minimum smoking history of 15 pack-years and may pro-
vide additional data to determine the minimum smoking his-
tory appropriate for screening.
DEFINING A POSITIVE RESULT ON LDCT AND 
FOLLOw-UP OF A POSITIVE RESULT
Recommendation 2: Positive 
Result and Follow-Up
•  Screening modality: Screening for lung cancer should be 
done using an LDCT multidetector scanner with the fol-
lowing parameters: 120 to 140 kVp, 20 to 60 mAs, with 
an average effective dose of 1.5 mSv or less.
•  Collimation should be 2.5 mm or less.
•  Definition of a positive result: A nodule size of 5 mm 
or more found on LDCT indicates a positive result and 
warrants a 3-month follow-up CT. Nodules of 15 mm or 
more should undergo immediate further diagnostic pro-
cedures to rule out definitive malignancy.
•  Appropriate follow-up of a positive result: Follow-up CT 
of a nodule should be done at 3 months as a limited LDCT 
scan (i.e., only a slab covering the nodule will be scanned, 
not the entire chest). The Lung Cancer Diagnosis Pathway 
should be consulted for guidance on clinical workup.
Key Evidence
•  Most of the studies published since 2008 used multi-
detector CT scanners. The voltage ranged from 100 to 
140 kVp, with all but one study using 120 to 140 kVp. 
The current ranged from 20 to 100 mAs, with all but 
one study not exceeding 60 mAs. The average effective 
dose was reported in five studies and ranged from 0.6 to 
1.5 mSv.7 The NLST used multidetector scanners with 
a minimum of four channels, 120 to 140 kVp, 20 to 30 
mAs, and an average effective dose of 1.5 mSv.4
•  Among the studies, collimation ranged from 0.75 to 
10 mm.7 Collimation in the NLST was 2.5 mm or less.4
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•  Nodule size found on LDCT warranting further investi-
gation ranged from a minimum size of any diameter to 
a maximum of more than 15 mm.7 In the NLST, nodules 
measuring 4 mm or more received further work up.4
•  Nine studies defined tumor growth. Growth can be deter-
mined with calliper measurements of diameter (6 studies) 
or three-dimensional volume measurements (4 studies). 
One RCT and one single-arm study described significant 
growth as an increase in tumor diameter of 1 mm or more. 
Three single-arm studies described significant growth as an 
increase in diameter in at least one dimension. Two RCTs 
described growth as a change in tumor volume of 25% 
or more. One single-arm study defined growing lesions as 
those with volume doubling time between 30 and 400 days 
and another used tumor volume and time between high-
resolution CT scans to calculate doubling time.7 A defini-
tion of growth was not reported in the NLST.
•  Guidance on the presentation and clinical workup of 
a lung cancer diagnosis is detailed in the Cancer Care 
Ontario (CCO) Lung Cancer Diagnosis Pathway.10
Justification
•  For screening modality, the parameters listed in the rec-
ommendations are derived from the NLST and ongoing 
studies.
•  With respect to collimation, newer scanners are able to 
provide 1 mm collimation with a short breath-hold time, 
but a large amount of images are produced, making 
scrolling and reading cumbersome. Currently, the colli-
mation used in the NLST is recommended.With respect 
to nodule size warranting further investigation, the rec-
ommendation deviates from the parameters of the NLST. 
In general, the smaller the nodule that defines a positive 
scan, the larger the number of positive scans, and the 
larger the number of false-positive results and unneces-
sary investigations for benign nodules. On the basis of 
a 4-mm threshold, 7191 of 26,309 scans (27.3%) in the 
NLST were positive. Six thousand nine hundred twenty-
one of the positive results (96%) were false positive. 
A 5-mm threshold will lower the rate of false-positive 
results, and if nodules between 4 and 5 mm are assessed 
on an annual scan, it is unlikely a significant finding will 
be missed. A prospective study of 1035 high-risk indi-
viduals found that nodules less than 5 mm identified by 
LDCT could be safely monitored at 1-year intervals.11 A 
retrospective study of two cohorts of patients (n = 1000 
and n = 1897) determined that had no immediate atten-
tion been given to nodules between 3 and 5 mm until 
the first annual repeat screening, immediate further 
workup would have been recommended in only 13% 
of patients rather than the 28% who received diagnos-
tic interventions.12 Raising the threshold for a positive 
scan from a diameter of 4 mm to a diameter of 5 mm 
will help lower the false-positive rate without sacrific-
ing the early detection of curable lung cancers. A recent 
study has suggested that increasing the threshold for a 
positive scan to 7 or 8 mm may decrease further workup 
without delaying diagnosis.13 This will be revisited in 
future versions of this guideline when more information 
becomes available.
•  The recommended follow-up is based on common stan-
dard of care actions in the presence of positive findings. 
Short-term follow-up CT scans are recommended in the 
event of a positive screening CT scan to assess the growth 
of a parenchymal nodule. These CT scans do not need to 
cover the entire chest; it is sufficient to limit the scan to 
the location of a nodule (i.e., a slab of a few centimeters 
covering the location of the nodule). This can substan-
tially decrease the radiation exposure to the patient.
Recommendation 3: LDCT Screening Interval
•  Recommendation 3: Persons at high risk for lung cancer 
should commence screening with an initial LDCT scan 
followed by annual screens for 2 consecutive years, and 
then once every 2 years after each negative (−ve) scan.
 
≥30 pack-y
 aA positive (+ve) test is defined as a solid nodule 5 mm or 
more or a nonsolid nodule (part solid or ground glass) of 
8 mm or more.
 bIf the nodule appearance dictates a different approach 
(e.g., bronchoscopy or positron emission tomography), this 
can be chosen at the discretion of the reading physician.
 cDoubling time of between 30 and 400 days.
 dLung Cancer Diagnosis Pathway.10
Key Evidence
•  LDCT was done on an annual basis in 18 studies; in years 1, 
2, and 4 in one study; every 6 months in one study, and after 
2 years in one study.7 The NLST conducted LDCT screens 
annually for 3 years.4
•  The Multicentric Italian Lung Detection (MILD) trial did 
not demonstrate a shift to higher-stage disease with bien-
nial screening compared with annual screening. Of 49 lung 
cancers, 20 were detected in the biennial group and 29 in 
the annual group.14
Justification
•  The current evidence stems from research studies on 
lung cancer screening, which by definition have a begin-
ning and an end (e.g., in the case of the NLST, 3 rounds 
of screening). This guideline, however, extends this 
evidence to a screening program, which does not have 
a defined end. The annual to biennial approach is based 
on best evidence balancing expected benefit from regular 
scanning with accumulated harm from costs, radiation, 
and burden on the health care system.
•  The current evidence is not sufficient to confirm the ben-
efit of a specific screening interval. The recommendation 
of annual screening for 3 years is subject to change when 
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longer-term trial evidence or further stratification meth-
ods become available from the NELSON trial.
Organized versus Opportunistic Screening
The decision to implement an organized, population-
based screening program involves many factors, not just the 
existence of supportive RCT clinical evidence. However, 
because the benefit of screening to date has only been dem-
onstrated in the context of an organized screening effort (i.e., 
a randomized clinical trial that compared 2 types of screen-
ing technology), it is the opinion of the Working Group that 
screening should be conducted in a manner similar to the 
NLST trial, that is, in an organized fashion. The American 
Society of Clinical Oncology (ASCO) guideline7 also sup-
ports screening of high-risk individuals, but only in the 
settings that can deliver comprehensive care such as that pro-
vided to NLST participants. The NLST authors themselves 
advise restraint in contemplating lung cancer screening rec-
ommendations on the basis of the NLST findings, claim-
ing the need for rigorous analysis of the cost-effectiveness 
of LDCT, and the weighing of the reduction in mortality 
against the harms of positive screening results, overdiagno-
sis, and cost.4 However, we are aware that these issues would 
be examined by provincial policy makers before screening 
policy decisions are made and approved.
Because of the potential harm that may arise with 
LDCT screening done contrary to the recommendations men-
tioned above, a program is required that explicitly describes 
the target population that will benefit the most, the referral 
process, the frequency and duration of screening, the loca-
tions where screening may take place, the personnel involved 
in performing and interpreting the scans, and the precise cri-
teria that define a positive scan. The inclusion of smoking ces-
sation counseling within the screening program is crucial. If 
elements of data collection and monitoring, quality assurance, 
and evaluation are built into the screening program from the 
start, it can be modified while in operation.
Opportunistic screening takes the form of CT scans 
applied to individuals who are asymptomatic, may not qualify 
for the test, or are referred on an ad hoc basis outside of a 
programmatic structure. These scans often include contrast, 
are not done with the low-dose technique, and lack appropri-
ate follow-up of detected lung nodules. This type of screen-
ing results in unnecessarily high radiation to the individual, 
potential side effects from contrast, and invasive procedures 
for potentially benign lesions. The Working Group believes 
strongly that screening outside a center that has experience 
and expertise in identifying the high-risk population, inter-
preting results, counselling patients, and performing the 
appropriate diagnostic techniques is ill advised. Such ad hoc 
screening will lead to an increase in the false-positive rate and 
in periprocedure morbidity and mortality, and will threaten to 
mitigate some or all of the benefits of the screening process.
DISCUSSION
The Lung Cancer Screening Working Group believes 
that the benefits of screening high-risk populations for lung 
cancer with LDCT outweigh the harms. The benefits stem 
from the documented improvement in mortality observed in 
the NLST showing that LDCT can not only detect small, early-
stage lung cancers, but also facilitate curing an individual 
of lung cancer. The harms stem from the investigation itself 
(radiation exposure) and the sequelae from the false-positive 
results (detection of lung nodules that ultimately turn out to 
be benign), and the risk associated with diagnostic evaluation 
(in the NLST, the frequency of death within 60 days of a diag-
nostic evaluation was eight per 10,000 individuals screened by 
LDCT and five per 10,000 screened by CXR4).
We address the concern over radiation exposure by rec-
ommending a low-dose regimen and by increasing the screen-
ing interval to every 2 years after three negative annual scans. 
We also suggest that the follow-up CT of a suspicious nod-
ule be done as a limited scan to further reduce the radiation 
exposure.
We address the impact of false-positive results by the 
definition of a positive CT scan: We intentionally deviated 
from the parameters of the NLST in this instance. In the 
NLST, the threshold for a positive result was a nodule of 4 mm 
or more in diameter. At baseline more than 27% of the screen-
ing tests were positive and 96% of those were false-positive 
results. By increasing the threshold of a positive test to 5 mm, 
the rate of positive baseline scans can be reduced to less than 
20% while still detecting early-stage, curable lung cancers. 
We also recommend a follow-up algorithm of CT-detected 
nodules, which is simple and straightforward based on size 
and growth and results in an extremely low rate of invasive 
procedures for benign lesions.15
Lung cancer screening with LDCT is recommended 
and can be most effectively and safely offered through an 
organized screening program and administered by special-
ized centers with multidisciplinary care teams. To determine 
whether or not a population-based screening program is 
appropriate for Ontario will require the CCO Prevention and 
Cancer Control division to investigate the other criteria rel-
evant to the decision-making process. Priorities will include 
long-term safety and effectiveness, cost effectiveness, and 
available resources.
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